Clinical trial
A Phase I/II, Multi-center, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects With Cystic Fibrosis
NCT02718495 is registered in ClinicalTrials.gov with Proteostasis Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II, Multi-center, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects With Cystic Fibrosis
- Lead sponsor
- Proteostasis Therapeutics, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- July 19, 2016
- Completion date
- November 28, 2017
- Enrollment
- 56 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.